Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by M. V. Zhuravleva
Pharmacoeconomic Evaluation of PD-L1 Receptor Inhibitors for the Second Line Treatment of Metastatic Non-Small Cell Lung Cancer
Medical Technologies. Assessment and Choice
Related publications
Real-World Evidenceand Clinical Observations of the Treatment of Advanced Non-Small Cell Lung Cancer With PD-1/PD-L1 Inhibitors
Scientific Reports
Multidisciplinary
Treatment Paradigms for Patients With Metastatic Non-Small-Cell Lung Cancer: First-, Second-, and Third-Line
Current Oncology
Oncology
The Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer
Lung Cancer: Targets and Therapy
Oncology
Immunotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
Cn5 - Cost-Effectiveness of Pembrolizumab Versus Standard-Of-Care Chemotherapies for First-Line Treatment of Pd-L1 Positive (≥50%) Metastatic Non-Small Cell Lung Cancer in France
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Design of PD-L1 Inhibitors for Lung Cancer
Bioinformation
PD-1/PD-L1: A Novel Target for Immunotherapy in Patients With Advanced and Metastatic Non-Small Cell Lung Cancer
Medicinski podmladak
Pharmacoeconomic Study of Pembrolizumab and Nivolumab in the Second Line of Therapy of Advanced Non-Small Cell Lung Cancer
Effective Pharmacotherapy
